Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.
Olopathadine, a newly developed histamine H1-receptor antagonist, was compared with cetirizine in its suppressive effects on histamine-induced wheal and flare reaction using an iontophoresis technique in a double-blind, crossover, placebo-controlled fashion. As a result, olopathadine was found to have effects comparable to cetirizine. This finding may predict the efficacy of this new H1-antagonist in treating pruritic skin diseases.
Morita
Eishin
E
Department of Dermatology, School of Medicine, Shimane University, Enya-cho 89-1, Izumo 693-8501, Japan.
Matsuo
Hiroaki
H
Zhang
Yan
Y
D000284:Administration, Oral; D000328:Adult; D017332:Cetirizine / Q000008:administration & dosage*; D018592:Cross-Over Studies; D003990:Dibenzoxepins / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007478:Iontophoresis; D008297:Male; D000069605:Olopatadine Hydrochloride; D013997:Time Factors; D016896:Treatment Outcome
D003990:Dibenzoxepins; D006634:Histamine H1 Antagonists; D000069605:Olopatadine Hydrochloride; D006632:Histamine; D017332:Cetirizine